• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

byConstance Wu
February 18, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma.

2. The incidence of serious adverse events was similar between both groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In advanced urothelial carcinoma, platinum-based chemotherapy and immunotherapy are the first and second line therapies. The optimal regiment after progression is unclear. Enfortumab vedotin is an antibody directed against nectin-4, which has high expression in urothelial carcinoma and is thought to be a contributor to cancer growth. In this phase 3, open-label clinical trial, for patients with advanced carcinoma who previously progressed on chemotherapy and PD-1/PD-L1 inhibitor, patients were either randomized to enfortumab vedotin or standard chemotherapy. Patients treated with enfortumab vedotin lived longer compared to standard chemotherapy and had better overall response rates. High-grade adverse events were similar among both groups; the most common being maculopapular rash, decreased neutrophil counts, and fatigue in the enfortumab vedotin group. However, it is unclear how enfortumab vedotin compares to FGFR inhibitors in tumors with a susceptible mutation. Overall, this trial demonstrated the superior effect of enfortumab vedotin in the treatment of refractory urothelial carcinoma when compared to standard single-agent chemotherapy.

Click here to read the study in the NEJM

Relevant Reading: Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

RELATED REPORTS

#VisualAbstract: Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma

Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma

#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma

In-Depth [randomized controlled trial]: This was a phase three, randomized, open-label trial of 608 patients randomized to either enfortumab vedotin or single-agent standard chemotherapy (docetaxel, paclitaxel, or vinflunine). The primary endpoint was overall survival. 134 deaths occurred in the enfortumab vedotin group (median survival, 12.88 months) and 167 deaths (median survival, 8.97 months) occurred in the chemotherapy group. The hazard ratio (HR) for death was 0.70 (95% confidence interval [CI] 0.56 to 0.89, P = 0.001). Progression-free survival showed the same trend of superiority for enfortumab vedotin. The overall response rate was 40.6% in the enfortumab vedotin group (95% CI, 34.9 to 46.5) and 17.9% (95% CI, 13.7 to 22.8) in the chemotherapy group (p < 0.001). Adverse events were common and similar between both groups (enfortumab vedotin group, 93.8%; chemotherapy group, 91.8%). The most frequent grade 3 or higher events in the enfortumab vedotin group was maculopapular rash (7.4%), fatigue (6.4%), and decreased neutrophil count (6.1%). The most frequent grade 3 or higher events in the chemotherapy group were decreased neutrophil count (13.4%), anemia (7.6%), decreased white cell count (6.9%), neutropenia (6.2%), and febrile neutropenia (5.5%). Overall, while the safety profile of the enfortumab vedotin group does pose some caution, the efficacy of this regiment is superior to standard chemotherapy.

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: enfortumabEnfortumab vedotinurothelial carcinomavedotin
Previous Post

Progression of COVID-19 reduced after high-titer convalescent plasma administration

Next Post

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

RelatedReports

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
StudyGraphics

#VisualAbstract: Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma

December 29, 2023
Minisling non-inferior to transobturator sling
Oncology

Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma

November 27, 2023
#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
StudyGraphics

#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma

October 27, 2023
Quick Take: Erdafitinib in locally advanced or metastatic urothelial carcinoma
Oncology

Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

February 12, 2021
Next Post
#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

#VisualAbstract: Skin biopsy rates have disproportionately increased compared to cancer treatments between 1993-2016

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Novartis and Sanofi Urge EU to Raise Drug Prices
  • Physical therapy vs. glucocorticoid injection in patients with meniscal tears and knee osteoarthritis
  • Eli Lilly Takes Legal Action Against Telehealth Startups
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.